Your session is about to expire
← Back to Search
Mesenchymal Stem Cell Therapy
Cellgram™ (Bone marrow-derived MSCs) for Liver Cirrhosis
Phase 1
Waitlist Available
Led By Juan Gallegos-Orozco, Ph.D
Research Sponsored by Pharmicell Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Summary
This trial is testing a cell therapy called Cellgram™ for patients with severe liver damage from alcohol use. The therapy involves injecting cells from the patient's own bone marrow into their liver to help it heal.
Eligible Conditions
- Liver Cirrhosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Serious Adverse Events
Secondary study objectives
Chronic liver disease as assessed by the Child-Pugh score
How well the Liver is functioning
Incidence of Adverse Events
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Cellgram™ (Bone marrow-derived MSCs)Experimental Treatment1 Intervention
Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10\^7 cells/10 mL (range: 4.5 x 10\^7 to 5.5 x 10\^7 cells/10 mL) via the hepatic artery.
Find a Location
Who is running the clinical trial?
Pharmicell Co., Ltd.Lead Sponsor
16 Previous Clinical Trials
730 Total Patients Enrolled
4 Trials studying Liver Cirrhosis
420 Patients Enrolled for Liver Cirrhosis
Juan Gallegos-Orozco, Ph.DPrincipal InvestigatorUniversity of Utah
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger